NATCO Pharma Reports Q2 FY27 Consolidated Financial and Operational Results
Natco Pharma Ltd 路 Investor Presentation 路 13 Nov 2026, 9:27 pm
NATCO Pharma Reports Q2 FY27 Consolidated Financial and Operational Results NATCO Pharma reported Q2 FY27 consolidated revenue of INR 10,194 Mn, down YoY from INR 14,630 Mn in Q2 FY26 but up QoQ from INR 7,944 Mn in Q1 FY27. EBITDA stood at INR 3,100 Mn with a 30.4% margin. Net profit reached INR 2,026 Mn, delivering an EPS of INR 11.31. International formulations contributed INR 6,684 Mn, while domestic formulations generated INR 1,457 Mn. The company raised its stake in Adcock Ingram to 49% and expanded its US pipeline to 29 Para IV filings, including 20+ FTFs.
Original exchange filing (PDF)
More announcements from Natco Pharma Ltd
- Intimation of Investor Meet 路 17 Nov 2026
- Audio link of Earnings Conference Call Q2FY27 路 14 Nov 2026
- Un audited Financial Results for the quarter and half year ended 30th September, 2026 路 13 Nov 2026
- 19th November, 2026 is the Record Date for the payment of 2nd Interim Dividend for FY 2026-27 路 13 Nov 2026
- Natco Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026 and declaration of 2nd Interim Dividend for FY 2026-27 路 13 Nov 2026
- Outcome of Board Meeting 路 13 Nov 2026
- Intimation of schedule of Concall 路 13 Nov 2026
- The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on November 04, 2026 for V C Nannapaneni 路 04 Nov 2026
